Cargando…

Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports

Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization’s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Isaac V., Makunts, Tigran, Moumedjian, Talar, Issa, Masara A., Abagyan, Ruben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644696/ https://www.ncbi.nlm.nih.gov/pubmed/33154498 http://dx.doi.org/10.1038/s41598-020-76258-0

Ejemplares similares

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data
por: Makunts, Tigran, et al.
Publicado: (2021)

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
por: Cohen, Isaac V., et al.
Publicado: (2021)

Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events
por: Makunts, Tigran, et al.
Publicado: (2022)

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
por: Makunts, Tigran, et al.
Publicado: (2023)

Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
por: Joulfayan, Haroutyun, et al.
Publicado: (2023)

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites
por: Makunts, Tigran, et al.
Publicado: (2020)

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory
por: Makunts, Tigran, et al.
Publicado: (2019)

Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis
por: Makunts, Tigran, et al.
Publicado: (2019)

How can proton pump inhibitors damage central and peripheral nervous systems?
por: Makunts, Tigran, et al.
Publicado: (2020)

Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain
por: Makunts, Tigran, et al.
Publicado: (2018)

Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety
por: Wollmer, M. Axel, et al.
Publicado: (2021)

Common osteoporosis drug associated with increased rates of depression and anxiety
por: Keshishi, Dro, et al.
Publicado: (2021)

Hydroxychloroquine- and chloroquine-related cardiovascular events
Publicado: (2020)

Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine
por: Ngai, Jamie, et al.
Publicado: (2022)

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids
por: Makunts, Tigran, et al.
Publicado: (2019)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
por: Makunts, Tigran, et al.
Publicado: (2022)

Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic
por: Dauner, Daniel G., et al.
Publicado: (2021)

Pharmacology of Chloroquine and Hydroxychloroquine
por: Browning, David J.
Publicado: (2014)

Chloroquine/hydroxychloroquine overdose
por: McKeever, Rita
Publicado: (2020)

An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19
por: Shahsavarinia, Kavous, et al.
Publicado: (2021)

Chloroquine and hydroxychloroquine for cancer therapy
por: Manic, Gwenola, et al.
Publicado: (2014)

Chloroquine, hydroxychloroquine and COVID-19
por: Erickson, T. B., et al.
Publicado: (2020)

Reported ADRs with chloroquine or hydroxychloroquine
Publicado: (2021)

Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine
por: Stevens, David M., et al.
Publicado: (2020)

Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review
por: Silva, Pedro Urquiza Jayme, et al.
Publicado: (2022)

More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine
por: Verheijen, S., et al.
Publicado: (2021)

Chloroquine and hydroxychloroquine in the context of COVID-19
por: Shukla, Ashutosh M, et al.
Publicado: (2020)

Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
por: Principi, Nicola, et al.
Publicado: (2020)

Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders
Publicado: (2022)

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022)

Chloroquine: Psychiatric adverse events: case report
Publicado: (2020)

Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
por: Gies, Vincent, et al.
Publicado: (2020)

Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management
por: Lebin, Jacob A., et al.
Publicado: (2020)

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
por: Marmor, Michael F.
Publicado: (2020)

COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
por: Marmor, Michael F.
Publicado: (2020)

Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic()
por: Jáuregui, Edwin
Publicado: (2021)

Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients
por: Mahmoudi, Javad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_91soidi46ee56ikbds4o80s85g